Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/200221_IR_Chugai_eRozlytrek_ROS1-NSCLC_Approval.pdf Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - February 21, 2020 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche's Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without (Source: World Pharma News)
Source: World Pharma News - February 19, 2020 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA grants priority review to Roche ’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanc ed non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by June 19, 2020.“In the IMpower110 study, Tecen...
Source: Roche Media News - February 19, 2020 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanc ed non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by June 19, 2020.“In the IMpower110 study, Tecen...
Source: Roche Investor Update - February 19, 2020 Category: Pharmaceuticals Source Type: news

FDA Grants Priority Review to Atezolizumab to Treat Advanced Non-Small Cell Lung Cancer
Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 19, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Beagles can "sniff out" lung cancer more accurately than "advanced technology"
(Natural News) Lung cancer is the second most common type of cancer and the leading cause of cancer death in both men and women in the United States. There are several types of lung cancer, but non-small cell (NSCLC) is the most common form. Since NSCLC is so deadly, early detection is vital if a... (Source: NaturalNews.com)
Source: NaturalNews.com - February 14, 2020 Category: Consumer Health News Source Type: news

Alternative to Alimta Coming for Mesothelioma Patients
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - February 12, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is a MET inhibitor being evaluated as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer (NSCLC)(1). (Source: World Pharma News)
Source: World Pharma News - February 12, 2020 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)(1) Substantial unmet need exists among patients with METex14 ... Biopharmaceuticals, Oncology Novartis, capmatinib, METex14, NSCLC, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2020 Category: Pharmaceuticals Source Type: news

FDA Grants Priority Review to Capmatinib for Non-Small Cell Lung Cancer
The FDA granted a priority review to capmatinib, a MET inhibitor being analyzed for the first-line treatment of previously treated patients with METex14-mutated advanced NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - February 11, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Summary report on small cell lung cancer research points to progress and challenges
(International Association for the Study of Lung Cancer) In 2017, a group of lung cancer experts posed the question: 'Can recent advances in tumor biology that have led to progress treating non-small cell lung cancer translate into improved outcomes for small cell lung cancer?'According to an article " New Approaches to Small Cell Lung Cancer Therapy : From the Laboratory to the Clinic, " published in the February issue of the Journal of Thoracic Oncology, the answer is " yes. " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Pemetrexed for Injection for Nonsquamous Non-Small Cell Lung Cancer
The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

'Fluorescent markers' to illuminate cancer begins Phase 3 clinical trials
(Purdue University) Purdue-discovered intraoperative molecular imaging used to illuminate and target non-small-cell lung cancer shows improved outcomes for 26% of patients in multi-institutional Phase 2 clinical trial, receives FDA fast track. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2020 Category: International Medicine & Public Health Source Type: news

Inhibition of Pathway May Lead to Prevention and Treatment of NSCLC
Researchers found that through inheritable changes of gene expression, chronic exposure to IL-1 β can promote lung cancer metastasis, without altering DNA sequence. (Source: CancerNetwork)
Source: CancerNetwork - February 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Biopsy of Pulmonary Large Cell Neuroendocrine Carcinoma Biopsy of Pulmonary Large Cell Neuroendocrine Carcinoma
Via a semiquantitative approach, the authors present biopsy criteria for differentiating pulmonary large cell neuroendocrine carcinoma from non-small cell lung carcinoma.American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2020 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Drug Trials Snapshots: ROZLYTREK
ROZLYTREK is a drug used to treat adult patients with a type of non-small cell lung cancer (NSCLC) which is caused by an abnormal ROS1 gene and, has spread to other parts of the body (metastatic) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 27, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drug Trials Snapshots: LORBRENA
LORBRENA is a drug used to treat patients with a type of non-small cell lung cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 27, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Revealed an alteration related to the loss of effectiveness of a treatment in lung cancer
(Josep Carreras Leukaemia Research Institute) Researchers from IJC reveal that non-smoking patients with lung cancer that have an alteration in RB1 and are treated with EGFR inhibitors, acquire resistance to treatment through the mechanism of histopathological transformation, either to non-small cell lung cancer (SCLC) or SLCL combined with a transformation to squamous cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 23, 2020 Category: Cancer & Oncology Source Type: news

High BMI Associated with Improved OS Following Atezolizumab in Advanced NSCLC Treatment
A recent study indicated that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials. (Source: CancerNetwork)
Source: CancerNetwork - January 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC
Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 21, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. (Source: World Pharma News)
Source: World Pharma News - January 17, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Spotlight report on molecular testing in advanced lung cancer
This spotlight audit investigates the efficacy and outcomes of molecular testing in patients with advanced non-small-cell lung cancer (NSCLC) in England covering 1,157 patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 16, 2020 Category: Consumer Health News Source Type: news

Study Uncovers Drug Combination for Sarcomatoid Mesothelioma
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - January 16, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Celecoxib Added to Concurrent Chemoradiation Not Effective for Patients with NSCLC
Although concurrent chemotherapy and radiation is considered standard care, treatment of locally advanced NSCLC continues to be challenging, leading researchers to search for patients who may benefit from the addition of cyclooxygenase 2 inhibitors. (Source: CancerNetwork)
Source: CancerNetwork - January 16, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Step Count Predicts Outcomes in Lung Cancer Step Count Predicts Outcomes in Lung Cancer
Activity levels as measured in daily steps was shown to predict survival in patients with locally advanced non-small cell lung cancer, but performance status did not.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 13, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Top-Line Data Reported for Pralsetinib in Patients with RET Fusion-Positive NSCLC
Data from the ongoing phase I/II ARROW clinical trial will be used to support a new drug application submission for pralsetinib to the FDA for the treatment of patients with RET fusion-positive non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Obesity Paradox With Immunotherapy in NSCLC Obesity Paradox With Immunotherapy in NSCLC
A new analysis shows that overweight and obese patients with NSCLC live longer than their normal weight counterparts following treatment with immunotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Is Lowering PD-L1 Threshold for Pembrolizumab a Good Idea? Is Lowering PD-L1 Threshold for Pembrolizumab a Good Idea?
What is the best treatment option for patients with advanced NSCLC and PD-L1 of 1-49% on tumor cells?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

F1CDx approved in Japan as a CDx of ROS1+NSCLC for Rozlytrek
Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/200102_IR_Chugai_Approval_ROS1_CDx_en.pdf Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - January 2, 2020 Category: Pharmaceuticals Source Type: news

Ceritinib cost  effective for ALK-positive advanced NSCLC in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2020 Category: Drugs & Pharmacology Source Type: news

BMI, Survival Linked in NSCLC Treated With Atezolizumab
Overall, progression - free survival improved for patients with high BMI; link strongest with high PD - L1 expression (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 27, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

BMI, Survival Linked in NSCLC Treated With Atezolizumab
FRIDAY, Dec. 27, 2019 -- Baseline high body mass index (BMI) is associated with improved survival in patients with non-small cell lung cancer (NSCLC) treated with atezolizumab, according to a study published online Dec. 26 in JAMA Oncology. Ganessan... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2019 Category: Pharmaceuticals Source Type: news

Being overweight 'could HELP cancer patients beat the disease'
Researchers at Flinders University in Australia found non-small-cell lung cancer patients given atezolizumab who had a BMI of 25 or more had up to a 32 per cent better chance of surviving. (Source: the Mail online | Health)
Source: the Mail online | Health - December 27, 2019 Category: Consumer Health News Source Type: news

High BMI may improve cancer survival
(Flinders University) Above average or high BMI -- often linked to cancers, diabetes, cardiovascular and other diseases -- may in some cases improve the chance of survival among certain cancers, new research from Flinders University indicates. Focusing on clinical trials of atezolizumab, a common immunotherapy treatment for non-small-cell lung cancer (NSCLC), the Australian cancer researchers found improved responsiveness to the drug in those with a high body mass index (BMI). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 26, 2019 Category: Cancer & Oncology Source Type: news

Moderate to Severe Depression Affects One-Third of Patients with NSCLC
To improve quality of life for patients with depression, researchers indicated it is crucial to provide referral and follow-up mental health care for patients with non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 26, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%)
On April 11, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA ®, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumo (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Standard of care chemoradiation for Stage III NSCLC is superior to two tested alternatives
(NRG Oncology) Lung cancer is the leading cause of cancer death in the United States and approximately 75-80% of all cases are non-small cell lung cancer (NSCLC). Of these, 30-40% are considered locally advanced and are categorized as either Stage IIIA or IIIB. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2019 Category: International Medicine & Public Health Source Type: news

Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
(University of Colorado Anschutz Medical Campus) Pooled analysis of three phase 1 and 2 clinical trials show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2019 Category: Cancer & Oncology Source Type: news

Frequency and Outcomes of Brain Metastases in Patients With HER2-Mutant Lung Cancers
Patients with metastatic non-small cell lung cancer who harbor HER2-mutations may develop brain metastases more frequently during treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 10, 2019 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Moderate, Severe Depressive Symptoms Common in Lung Cancer
MONDAY, Dec. 9, 2019 -- For newly diagnosed patients with non-small cell lung cancer (NSCLC), depressive symptoms are common and often accompanied by other symptoms, according to a study published online Nov. 21 in Lung Cancer. Barbara L. Andersen,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2019 Category: Pharmaceuticals Source Type: news

FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 5, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Receipt of Surgery for Early NSCLC Varies by County
25 percent absolute difference found between lowest, highest surgery receipt - rate counties in Massachusetts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2019 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Surgery, Journal, Source Type: news

First - Line Osimertinib May Up Survival in EGFR - Mutated NSCLC
For previously untreated disease, overall survival longer with osimertinib versus comparator EGFR - TKIs (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

First-Line Osimertinib May Up Survival in EGFR-Mutated NSCLC
THURSDAY, Dec. 5, 2019 -- For patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an EGFR mutation, overall survival is longer for treatment with osimertinib rather than comparator tyrosine kinase inhibitors of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2019 Category: Pharmaceuticals Source Type: news

Receipt of Surgery for Early NSCLC Varies by County
THURSDAY, Dec. 5, 2019 -- There is considerable variation across counties in receipt of curative-intent surgery for early-stage non-small cell lung cancer (NSCLC), according to a study published online Dec. 5 in CHEST. Helmneh M. Sineshaw, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2019 Category: Pharmaceuticals Source Type: news

Balazs Halmos, MD, MS, Discusses Metastatic Non-Small Cell Lung Cancer Advancements
Balazs Halmos, MD, MS, from Montefiore Albert Einstein Cancer Center, discussed advancements in treatment of metastatic non-small cell lung cancer at the Annual New York Lung Cancers Symposium ®. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2019 Category: Cancer & Oncology Authors: Balazs Halmos, MD, MS Source Type: news

FDA Approves Atezolizumab Again for mNSCLC FDA Approves Atezolizumab Again for mNSCLC
The US Food and Drug Administration approved the immunotherapy as initial treatment of metastatic nonsquamous non-small cell lung cancer (mNSCLC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves Roche ’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - December 4, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2019 Category: Pharmaceuticals Source Type: news